Literature DB >> 21281215

Efficacy of oral transmucosal and intravenous administration of buprenorphine before surgery for postoperative analgesia in dogs undergoing ovariohysterectomy.

Jeff C Ko1, Lynetta J Freeman, Michele Barletta, Ann B Weil, Mark E Payton, Brenda M Johnson, Tomohito Inoue.   

Abstract

OBJECTIVE: To compare the efficacy of preoperative administration of buprenorphine (via oral transmucosal [OTM] and IV routes) for postoperative analgesia in dogs undergoing ovariohysterectomy.
DESIGN: Prospective, randomized, blinded study. ANIMALS: 18 dogs undergoing routine ovariohysterectomy. PROCEDURES: Dogs were allocated to 3 groups (6 dogs/group) and were assigned to receive buprenorphine (20 μg/kg [9.09 μg/lb], IV; a low dose [20 μg/kg] via OTM administration [LOTM]; or a high dose [120 μg/kg [54.54 μg/lb] via OTM administration [HOTM]) immediately before anesthetic induction with propofol and maintenance with isoflurane for ovariohysterectomy. Postoperative pain was assessed by use of a dynamic interactive pain scale. Dogs were provided rescue analgesia when postoperative pain exceeded a predetermined threshold. Blood samples were collected, and liquid chromatography-electrospray ionization-tandem mass spectrometry was used to determine plasma concentrations of buprenorphine and its metabolites. Data were analyzed with an ANOVA.
RESULTS: Body weight, surgical duration, propofol dose, isoflurane concentration, and cardiorespiratory variables did not differ significantly among treatment groups. Number of dogs requiring rescue analgesia did not differ significantly for the HOTM (1/6), IV (3/6), and LOTM (5/6) treatments. Similarly, mean ± SEM duration of analgesia did not differ significantly for the HOTM (20.3 ± 3.7 hours), IV (16.0 ± 3.8 hours), and LOTM (7.3 ± 3.3 hours) treatments. Plasma buprenorphine concentration was ≤ 0.60 ng/mL in 7 of 9 dogs requiring rescue analgesia. CONCLUSIONS AND CLINICAL RELEVANCE: Buprenorphine (HOTM) given immediately before anesthetic induction can be an alternative for postoperative pain management in dogs undergoing ovariohysterectomy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281215     DOI: 10.2460/javma.238.3.318

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  10 in total

1.  Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (Macaca mulatta).

Authors:  Alexis L Mackiewicz; Gregory W Salyards; Heather K Knych; Ashley E Hill; Kari L Christe
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-06-21       Impact factor: 1.232

2.  Clinical efficacy of sustained-release buprenorphine with meloxicam for postoperative analgesia in beagle dogs undergoing ovariohysterectomy.

Authors:  Elizabeth A Nunamaker; DeAnne F Stolarik; Junli Ma; Amanda S Wilsey; Gary J Jenkins; Chris L Medina
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

3.  Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica).

Authors:  Allison J Thiede; Kelly D Garcia; DeAnne F Stolarik; Junli Ma; Gary J Jenkins; Elizabeth A Nunamaker
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-11       Impact factor: 1.232

4.  Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).

Authors:  Elizabeth A Nunamaker; Lisa C Halliday; David E Moody; Wenfang B Fang; Matthew Lindeblad; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

Review 5.  Analgesic use in nonhuman primates undergoing neurosurgical procedures.

Authors:  Louis DiVincenti
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

6.  Levetiracetam rectal administration in healthy dogs.

Authors:  R K Peters; T Schubert; R Clemmons; T Vickroy
Journal:  J Vet Intern Med       Date:  2014-01-13       Impact factor: 3.333

7.  Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial.

Authors:  Paulo Vinicius Steagall; Hélène Louise Marcelle Ruel; Tomoyo Yasuda; Beatriz Paglerani Monteiro; Ryota Watanabe; Marina Cayetano Evangelista; Francis Beaudry
Journal:  BMC Vet Res       Date:  2020-05-24       Impact factor: 2.741

8.  Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs.

Authors:  Hiroko Enomoto; Lydia Love; Melanie Madsen; Amber Wallace; Kristen M Messenger
Journal:  J Vet Pharmacol Ther       Date:  2022-04-21       Impact factor: 1.567

9.  Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus).

Authors:  Niora J Fabian; David E Moody; Olga Averin; Wenfang B Fang; Morgan Jamiel; James G Fox; Monika A Burns; Jennifer L Haupt
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-07-19       Impact factor: 1.232

10.  Oral Transmucosal or Intramuscular Administration of Dexmedetomidine-Methadone Combination in Dogs: Sedative and Physiological Effects.

Authors:  Daniela Gioeni; Federica Alessandra Brioschi; Federica Di Cesare; Vanessa Rabbogliatti; Martina Amari; Sergio Zanzani; Petra Cagnardi; Giuliano Ravasio
Journal:  Animals (Basel)       Date:  2020-11-06       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.